ImmunityBio Faces Serious Legal Challenges and Market Drop Over Misleading Drug Claims

Legal Challenges and Market Implications for ImmunityBio, Inc.

In recent developments, ImmunityBio, Inc. (NASDAQ: IBRX) has found itself in hot water, facing a securities class action lawsuit prompted by the company’s potentially misleading claims regarding its lead product, Anktiva. The situation escalated following a warning from the U.S. Food and Drug Administration (FDA) that the statements made by the company regarding Anktiva’s efficacy were deemed false and misleading.

Background of the Lawsuit

The class action aims to represent investors who acquired ImmunityBio securities between January 19, 2026, and March 24, 2026. This legal move comes on the heels of a revelation that the FDA issued a warning letter highlighting concerns over remarks made by Dr. Patrick Soon-Shiong, ImmunityBio’s executive chairman and Chief Scientific and Medical Officer. The claims in question suggested that Anktiva could treat not just non-muscle invasive bladder cancer (NMIBC), for which it is FDA-approved, but potentially all forms of cancer.

Impact of FDA Warning

The FDA’s warning letter, released on March 24, 2026, explicitly stated that the promotional materials, including a podcast and a television advertisement featuring Dr. Soon-Shiong, created misleading impressions about Anktiva’s capabilities. According to the FDA, these materials falsely suggested that the treatment could cure or even prevent cancer entirely, which it had not been proven to accomplish.

Furthermore, the FDA chastised ImmunityBio for failing to present pivotal information about Anktiva’s approved indications. The implications of these misleading claims were significant, causing ImmunityBio's stock price to plummet by over 21%, equating to nearly a $2 billion decline in market capitalization. Such a dramatic loss indicates serious investor repercussions and public health concerns, highlighting the legal and ethical obligations companies have regarding the claims they make about their products.

The Role of Hagens Berman

National shareholders’ rights firm Hagens Berman is at the forefront of the lawsuit, investigating claims that ImmunityBio might have violated federal securities regulations by making these potentially harmful assertions about Anktiva. The firm is actively urging investors who have experienced considerable losses to step forward and share their experiences. Additionally, Hagens Berman is seeking witnesses who might assist in furthering the investigation.

Reed Kathrein, the partner leading the investigation, commented, "We are looking into whether ImmunityBio intentionally misled investors regarding the efficacy and indications of Anktiva." This scrutiny raises fundamental questions about corporate accountability and investor protection in the biotech industry.

Future Implications for ImmunityBio

ImmunityBio's market challenges and the ongoing lawsuit pose potential long-term repercussions for the company. The allegations may not only affect its stock performance and investor relations but could also influence regulatory scrutiny of its future communications about treatment efficacy. With a lead plaintiff deadline set for May 26, 2026, the upcoming months will be crucial for both the company and its investors as the legal landscape unfolds.

Moreover, the situation serves as a cautionary tale in the biotech sector, illustrating the delicate balance between promoting innovative treatments and ensuring that claims made to the public are accurate and transparent. Moving forward, it is imperative for ImmunityBio and similar companies to prioritize clarity, accuracy, and honesty in their communications to uphold both investor confidence and public trust.

Conclusion

As ImmunityBio navigates these turbulent waters, the implications of this lawsuit will likely reshape not only the company’s future but also the broader biotechnology landscape where transparency is increasingly under scrutiny. The intersection of investor rights and corporate accountability will undoubtedly continue to be a developing narrative as this case unfolds, impacting stakeholders across the board.